Browsing Radiotherapy and Imaging by author "Harrington, Kevin"
Now showing items 121-140 of 158
-
Radiotherapy enhances responses of lung cancer to CTLA-4 blockade.
Wilkins, A; McDonald, F; Harrington, K; Melcher, A (BMC, 2019-03-06)Formenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with palliative radiotherapy in 39 patients with non-small cell ... -
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna, H; Robinson, M; Hartley, A; Kong, A; Foran, B; et al. (ELSEVIER SCIENCE INC, 2019-01-05)BACKGROUND: The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed ... -
Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah, AB; Gulliford, SL; Morden, J; Newbold, KL; Bhide, SA; et al. (ELSEVIER SCIENCE LONDON, 2016-09-01)AIMS: To establish whether there is a difference in recovery of salivary function with bilateral superficial lobe parotid-sparing intensity-modulated radiotherapy (BSLPS-IMRT) versus contralateral parotid-sparing IMRT ... -
Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T.
Panek, R; Welsh, L; Dunlop, A; Wong, KH; Riddell, AM; et al. (WILEY-BLACKWELL, 2016-07-01)PURPOSE: To determine whether quantitation of T2* is sufficiently repeatable and sensitive to detect clinically relevant oxygenation levels in head and neck squamous cell carcinoma (HNSCC) at 3T. MATERIALS AND METHODS: Ten ... -
Reply to N.F. Saba and S.J. Wong.
Harrington, KJ; Bourhis, J (2016-06) -
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
Goldmacher, GV; Khilnani, AD; Andtbacka, RHI; Luke, JJ; Hodi, FS; et al. (AMER SOC CLINICAL ONCOLOGY, 2020-08-10) -
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).
Nutting, CM; Morden, JP; Beasley, M; Bhide, S; Cook, A; et al. (ELSEVIER SCI LTD, 2018-11-01)PURPOSE: About 40-60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the ... -
RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.
Smith, HG; Jamal, K; Dayal, JH; Tenev, T; Kyula-Currie, J; et al. (WILEY, 2020-06-08)Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune ... -
Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study.
Vasiliadou, I; Breik, O; Baker, H; Leslie, I; Sim, VR; et al. (MDPI, 2021-03-19)Nivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based ... -
Standardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer.
Gujral, DM; Long, M; Roe, JWG; Harrington, KJ; Nutting, CM (ELSEVIER SCIENCE LONDON, 2017-01-01)AIMS: Recently, carotid-sparing intensity-modulated radiotherapy (IMRT) for early laryngeal glottis (T1/T2N0M0) cancer has generated interest in the hope of avoiding long-term carotid toxicity, as well as concerns relating ... -
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).
Marabelle, A; Andtbacka, R; Harrington, K; Melero, I; Leidner, R; et al. (OXFORD UNIV PRESS, 2018-11-01)A European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 8 March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry and 2 clinicians who were ... -
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
Evgin, L; Huff, AL; Kottke, T; Thompson, J; Molan, AM; et al. (AMER ASSOC CANCER RESEARCH, 2019-05-01)Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). ... -
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.
Kottke, T; Evgin, L; Shim, KG; Rommelfanger, D; Boisgerault, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-11-01)Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition ... -
Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins, C; Simpson, GR; Rogers, W; Relph, K; Harrington, K; et al. (NATURE PUBLISHING GROUP, 2018-05-01)There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. This progress ... -
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
Harrington, KJ; Kong, A; Mach, N; Chesney, JA; Fernandez, BC; et al. (AMER ASSOC CANCER RESEARCH, 2020-10-01)PURPOSE: The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, and only a minority of patients benefit from checkpoint immunotherapy. Talimogene laherparepvec ... -
Targeting HOX/PBX dimers in cancer.
Morgan, R; El-Tanani, M; Hunter, KD; Harrington, KJ; Pandha, HS (IMPACT JOURNALS LLC, 2017-05-09)The HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also ... -
Taste dysfunction following radiotherapy to the head and neck: A systematic review.
Gunn, L; Gilbert, J; Nenclares, P; Soliman, H; Newbold, K; et al. (ELSEVIER IRELAND LTD, 2021-04-01)BACKGROUND: An intact sense of taste provides pleasure, supports sustenance and alerts the body to toxins. Head and neck cancer (HNC) patients who receive radiotherapy (RT) are high-risk for developing radiation-induced ... -
The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Jou, J; Harrington, KJ; Zocca, M-B; Ehrnrooth, E; Cohen, EEW (AMER ASSOC CANCER RESEARCH, 2021-02-01)Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. Here, we ... -
The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures.
Richards, TM; Hurley, T; Grove, L; Harrington, KJ; Carpenter, GH; et al. (WILEY, 2017-10-01)OBJECTIVES: To describe parotid gland (PG) saliva organic and inorganic composition and flow rate changes, after curative intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC), and analyse the relationship ... -
The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective.
Wong, KH; Panek, R; Bhide, SA; Nutting, CM; Harrington, KJ; et al. (BRITISH INST RADIOLOGY, 2017-01-01)Head and neck cancer (HNC) is a challenging tumour site for radiotherapy delivery owing to its complex anatomy and proximity to organs at risk (OARs) such as the spinal cord and optic apparatus. Despite significant advances ...